B7-H3 CAR-T for Recurrent or Refractory Glioblastoma
Status:
Recruiting
Trial end date:
2024-07-01
Target enrollment:
Participant gender:
Summary
This is a randomized, parallel-arm, phase I/II study to evaluate the safety and efficacy of
B7-H3 CAR-T in between Temozolomide cycles comparing to Temozolomide alone in treating
patients with glioblastoma that has come back or does not respond to the standard treatment.
The antigen B7-H3 is highly expressed in glioblastoma of a subset of patients. B7-H3 CAR-T,
made from isolated patient peripheral blood mononuclear cells, can specifically attack
patient glioblastoma cells that expressing B7-H3.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Second Affiliated Hospital, School of Medicine, Zhejiang University
Collaborators:
BoYuan RunSheng Pharma (Hangzhou) Co., Ltd. Huizhou Municipal Central Hospital Huzhou Central Hospital Ningbo Yinzhou People's Hospital